Peginterferon alfa-2a - Roche
Alternative Names: PEG IFN-α-2a; PEG interferon-α-2a; PEG-IFN - Roche; Pegasys; Pegferon; Pegylated interferon-alpha-2a; R 442; RG 442; RG 964; RO 25-8310; RO 253036Latest Information Update: 05 Nov 2023
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Icahn School of Medicine at Mount Sinai; Roche; University of Pennsylvania
- Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
- Mechanism of Action Immunostimulants; Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B; Hepatitis C
- Phase II HIV-1 infections
- No development reported Chronic myeloid leukaemia; Essential thrombocythaemia; Hepatitis D; Polycythaemia vera
- Discontinued Malignant melanoma; Renal cell carcinoma
Most Recent Events
- 18 Oct 2021 Hoffmann-La Roche completes a phase III trial in Hepatitis B (In adolescents, In children) in United Kingdom, Ukraine, Russia, Poland, Italy, Israel, Germany, China, Bulgaria, Belgium, Australia, USA (SC) (NCT01519960)
- 08 Apr 2021 Registered for Hepatitis B (In adolescents, In children) in Iceland, Liechtenstein, Norway (SC)
- 08 Apr 2021 Registered for Hepatitis B (In adolescents, In children) in European Union (SC)